Pharmaceutical manufacturers are moving to a new way of containing the 340B drug discount program after their three-year attempt to restrict discounts to contract pharmacies apparently failed to achieve the desired results.
340B Plan B: Pharma Pivots To Rebate Pricing Model After Pharmacy Restrictions Fall Short
The manufacturer dispute with hospitals and US agency tasked with overseeing the outpatient drug discount program is entering a new phase.
More from Pricing Debate
More from Geography
• By
The weight management drug, Mysimba, continues to demonstrate a positive benefit-risk balance but the data available are not sufficient to fully determine the cardiovascular safety beyond 12 months. Meanwhile, Currax this month announced the publication of a peer-reviewed study of Mysimba that followed patients for over 4.7 years and found no evidence of excess cardiovascular risk.
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
• By
In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."